<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164971">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113397</url>
  </required_header>
  <id_info>
    <org_study_id>D14010</org_study_id>
    <secondary_id>CTBM100DUS02T</secondary_id>
    <nct_id>NCT02113397</nct_id>
  </id_info>
  <brief_title>Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung</brief_title>
  <official_title>Comparative Evaluation of Bacterial Diversity and Richness in the Cystic Fibrosis Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI™ Podhaler™) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI™ Podhaler™) and Aztreonam Lysine for Inhalation (Cayston™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize bacterial diversity and richness in the sputum
      of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous
      alternating therapy with TOBI™ Podhaler and Cayston™.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Simpson Diversity Index</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary estimate in our study is the mean effects of Continuous Alternating Therapy compared to Cyclic therapy on Simpson Diversity Index (SDI) averaged at month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial Relative Abundance</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using 454 pyrosequencing and quantitative polymerase chain reaction (qPCR) techniques, the relative abundance of various bacterial genera will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Continuous Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle Cayston 75 mg inhaled three times daily.  Repeat cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclic therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used.  Repeat cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOBI™ Podhaler™ 112 mg inhaled twice daily</intervention_name>
    <arm_group_label>Continuous Therapy</arm_group_label>
    <arm_group_label>Cyclic therapy</arm_group_label>
    <other_name>Tobramycin inhalation powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cayston 75 mg inhaled three times daily</intervention_name>
    <arm_group_label>Continuous Therapy</arm_group_label>
    <other_name>Aztreonam lysine solution for inhalation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cystic fibrosis confirmed by mutation analysis of the cystic fibrosis
             transmembrane conductance regulator gene

          -  Sputum or throat swab culture positive for Pseudomonas aeruginosa at or within 6
             months of enrollment

          -  Age ≥18 years

          -  Forced expiratory volume in one second (FEV1) 25-80 percent-predicted

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Inability to routinely expectorate sputum without induction by hypertonic saline

          -  Inability to provide or withdrawal of written informed consent

          -  History of aminoglycoside sensitivity or adverse reaction to inhaled antibiotics

          -  Serum creatinine ≥ 2.0 mg/dl

          -  Serum blood urea nitrogen (BUN) ≥40 mg/dl

          -  Pregnancy or lactating at screening

          -  History of systemic intravenous anti-Pseudomonal antibiotics within 28 days of
             enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alex H Gifford, M.D.</last_name>
    <phone>(603) 650-5533</phone>
    <email>alex.h.gifford@hitchcock.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer E. Helm, B.S.</last_name>
      <phone>603-650-8178</phone>
      <email>jennifer.e.helm@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa A Moulton, R.N.</last_name>
      <phone>(603) 650-8178</phone>
      <email>lisa.a.moulton@hitchcock.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alex H Gifford, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alix Ashare, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>H. Worth Parker, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard I Enelow, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG, Paster BJ, O'Toole GA. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol. 2012 Sep;194(17):4709-17. doi: 10.1128/JB.00566-12. Epub 2012 Jun 29.</citation>
    <PMID>22753064</PMID>
  </reference>
  <reference>
    <citation>Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O'Toole GA. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome. 2013 Nov 1;1(1):27. doi: 10.1186/2049-2618-1-27.</citation>
    <PMID>24451123</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Alex H. Gifford</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Sputum</keyword>
  <keyword>Tobramycin</keyword>
  <keyword>Aztreonam</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
